A new treatment for advanced colorectal cancer is being developed by a team of researchers at the University of Saskatchewan‘s College of Medicine.
Led by assistant professor Humphrey Fonge, the researchers created an assassin antibody — with attached radioactive molecules — that cling to a specific protein on colorectal cancer cells and kill them by releasing high energy.
“This is a personalized medicine approach enabling us to treat the cancer in a very pinpointed way, while sparing healthy tissue,” Fonge said in a press release.
“This could transform outcomes for many colorectal cancer patients including those at the advanced stages of the cancer.”
WATCH BELOW: Breast cancer screening mobile van helping women in rural and remote Sask.
According to U of S, colorectal cancer is the second leading cause of death from cancer in North America. Patients with advanced colorectal cancer generally have a life expectancy of around 24 to 30 months.
Get weekly health news
Current antibody drug therapies can slow down the spread of colorectal cancer, but do not destroy the existing cancer cells.
WATCH BELOW: Sobering results from new study on colorectal cancer
Fonge said their new treatment is a novel radio-immunotherapy approach.
He added their initial evaluation of the assassin antibody in mice has been very promising and they hope to move to human trials in two years.
The U of S team is planning to study whether the new antibody could be used to treat other cancers, including breast and pancreatic cancers, which express the same protein.
Comments